Company Filing History:
Years Active: 2025
Title: Julia Ding - Innovator in Isoelectric Focusing Sample Matrices
Introduction
Julia Ding is a prominent inventor based in Weston, MA (US). She has made significant contributions to the field of biochemistry, particularly in the analysis of PEGylated proteins. Her innovative work has led to the development of advanced sample matrices that enhance the accuracy and efficiency of protein characterization.
Latest Patents
Julia Ding holds a patent for an invention titled "Isoelectric focusing sample matrix." This patent describes icIEF sample matrices that facilitate the analysis of PEGylated proteins in their real conjugated states. The matrices include glycine, which aids in the separation of co-migrated PEGylated protein charge variants. Additionally, the inclusion of taurine improves the icIEF assay by reducing matrix-induced baseline interferences. The combination of glycine and taurine in the sample matrix allows for the effective separation of acidic and basic species from the main peak of PEGylated proteins. This innovation enables the identification, characterization, and quantification of discrete PEGylated protein species, achieving repeatability, linearity, accuracy, sample stability, and method robustness.
Career Highlights
Julia Ding is currently employed at Bristol-Myers Squibb Company, where she continues to advance her research in biochemistry and protein analysis. Her work has garnered attention for its practical applications in the pharmaceutical industry, particularly in drug development and protein therapeutics.
Collaborations
Throughout her career, Julia has collaborated with notable colleagues, including Xin Zhang and Letha Chemmalil. These collaborations have further enriched her research and contributed to the success of her innovative projects.
Conclusion
Julia Ding is a trailblazer in the field of biochemistry, with her patent on isoelectric focusing sample matrices representing a significant advancement in the analysis of PEGylated proteins. Her contributions continue to impact the pharmaceutical industry positively.